Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

International journal of cancer - 15 Nov 2017

Wang Bin, Lo U-Ging, Wu Kaijie, Kapur Payal, Liu Xiangyang, Huang Jun, Chen Wei, Hernandez Elizabeth, Santoyo John, Ma Shi-Hong, Pong Rey-Chen, He Dalin, Cheng Yi-Qiang, Hsieh Jer-Tsong

Abstract excerpt

The presence of androgen receptor variant 7 (AR-V7) variants becomes a significant hallmark of castration-resistant prostate cancer (CRPC) relapsed from hormonal therapy and is associated with poor survival of CRPC patients because of lacking a ligand-binding domain. Currently, it still lacks an effective agent to target AR-V7 or AR-Vs in general. Here, we showed that a novel class of agents (thailanstatins, TSTs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Burkholderia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prostatic Neoplasms, Castration-Resistant

Share to Protein Isoforms

Share to Pyrans

Share to Receptors, Androgen

Share to RNA Splicing

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 28722220
DOI: 10.1002/ijc.30893
PMCID: PMC5777133

Genes

TST

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.PMID 28722220Read ↗

AR Splicing Variants and Resistance to AR Targeting AgentsSemantic proximity Read ↗

Role of androgen receptor splice variants in prostate cancer metastasisSemantic proximity Read ↗

Decoding the androgen receptor splice variants.Semantic proximity Read ↗

<scp>Androgen receptor</scp> splice variant 7 in castration‐resistant prostate cancer: Clinical considerationsSemantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.Semantic proximity Read ↗

[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].Semantic proximity Read ↗

A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!Semantic proximity Read ↗

Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor SignalingSemantic proximity Read ↗

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate CancerSemantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

Emerging data on androgen receptor splice variants in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.